This is a Phase IV, single site, randomized, double masked, parallel control clinical trial of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for treatment of ocular surface inflammation due to meibomian gland dysfunction (MGD). Efficacy will be measured by in-vivo confocal microscopy, corneal fluorescein staining, grading of meibomian gland dysfunction and validated ocular symptom assessment questionnaire.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Ocular Surface Disease Index
Timeframe: Week 4 Time Point
Symptom Assessment iN Dry Eye (SANDE) Frequency Score
Timeframe: Week 4 Time Point
Symptom Assessment iN Dry Eye (SANDE) Severity Score
Timeframe: Week 4 Time Point
Corneal Fluorescein Staining Score
Timeframe: Week 4 Time Point